Cargando…

The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018

Genital warts (GWs) caused by the human papilloma virus (HPV) are a significant health problem due to high prevalence and rate of recurrence. Bivalent vaccine has been used since the start of the national vaccination program in 2013, making it feasible to study the GW burden in Finland. There is no...

Descripción completa

Detalles Bibliográficos
Autores principales: Gylling, Annette, Uusi-Rauva, Kristiina, Toppila, Iiro, Hiltunen-Back, Eija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384701/
https://www.ncbi.nlm.nih.gov/pubmed/37515019
http://dx.doi.org/10.3390/vaccines11071202
_version_ 1785081221768806400
author Gylling, Annette
Uusi-Rauva, Kristiina
Toppila, Iiro
Hiltunen-Back, Eija
author_facet Gylling, Annette
Uusi-Rauva, Kristiina
Toppila, Iiro
Hiltunen-Back, Eija
author_sort Gylling, Annette
collection PubMed
description Genital warts (GWs) caused by the human papilloma virus (HPV) are a significant health problem due to high prevalence and rate of recurrence. Bivalent vaccine has been used since the start of the national vaccination program in 2013, making it feasible to study the GW burden in Finland. There is no national and up-to-date information available on the prevalence and the burden of GWs in the various healthcare sectors in Finland. The present study investigated the prevalence, healthcare resource use, and direct medical costs of the treatment of GWs in Finland in 2018 using data in national healthcare registers. GW cases were identified based on diagnoses in public healthcare and GW-related prescription medications. Cost analysis included public healthcare contacts, procedures in private care, and medications. The study showed that approximately 12,000 GWs cases were treated in Finland in 2018. Since less than half of GW diagnoses were recorded in public healthcare registers, determining the exact costs was challenging. The estimated direct treatment costs in 2018 were 2.6 M€, which is higher than the previous estimation in Finland, yet still likely an underestimation of the true burden. These results provide information for the management of the GW burden in Finland.
format Online
Article
Text
id pubmed-10384701
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103847012023-07-30 The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018 Gylling, Annette Uusi-Rauva, Kristiina Toppila, Iiro Hiltunen-Back, Eija Vaccines (Basel) Article Genital warts (GWs) caused by the human papilloma virus (HPV) are a significant health problem due to high prevalence and rate of recurrence. Bivalent vaccine has been used since the start of the national vaccination program in 2013, making it feasible to study the GW burden in Finland. There is no national and up-to-date information available on the prevalence and the burden of GWs in the various healthcare sectors in Finland. The present study investigated the prevalence, healthcare resource use, and direct medical costs of the treatment of GWs in Finland in 2018 using data in national healthcare registers. GW cases were identified based on diagnoses in public healthcare and GW-related prescription medications. Cost analysis included public healthcare contacts, procedures in private care, and medications. The study showed that approximately 12,000 GWs cases were treated in Finland in 2018. Since less than half of GW diagnoses were recorded in public healthcare registers, determining the exact costs was challenging. The estimated direct treatment costs in 2018 were 2.6 M€, which is higher than the previous estimation in Finland, yet still likely an underestimation of the true burden. These results provide information for the management of the GW burden in Finland. MDPI 2023-07-05 /pmc/articles/PMC10384701/ /pubmed/37515019 http://dx.doi.org/10.3390/vaccines11071202 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gylling, Annette
Uusi-Rauva, Kristiina
Toppila, Iiro
Hiltunen-Back, Eija
The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018
title The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018
title_full The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018
title_fullStr The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018
title_full_unstemmed The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018
title_short The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018
title_sort burden of genital warts in finland: cross-sectional analysis of the prevalence and direct medical costs in 2018
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384701/
https://www.ncbi.nlm.nih.gov/pubmed/37515019
http://dx.doi.org/10.3390/vaccines11071202
work_keys_str_mv AT gyllingannette theburdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018
AT uusirauvakristiina theburdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018
AT toppilaiiro theburdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018
AT hiltunenbackeija theburdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018
AT gyllingannette burdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018
AT uusirauvakristiina burdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018
AT toppilaiiro burdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018
AT hiltunenbackeija burdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018